Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning Tablets for Preventing Recurrence of Diabetic Lower Extremity Arterial Disease
NCT07139639Phase 1Not yet recruiting
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- PE (Plant Extract)
01
Overview
Phase 1, randomised, double-blind trial of Guanxinning Tablet in lower extremity arterial disease (LEAD) (2 arms). Primary endpoint: Ulcer Recurrence Rate at 6 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
Guanxinning Tablet
03
Conditions
lower extremity arterial disease (LEAD)
Beyond the preview
Go deeper on NCT07139639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139639.